Abstract P4-08-10: Systematic expression analysis of the genes related to drug-resistance in isogenic docetaxel- and adriamycin-resistance breast cancer cell lines.

Background: We investigated molecular mechanisms behind astaxanthinmediated induction of apoptosis in breast cancer cell lines toward combination therapy against cancer drug resistance. Methods: Breast cancer cell lines were treated with serial concentrations of astaxanthin to determine its IC50. We used drug-design software to predict interactions between astaxanthin and receptor tyrosine kinases or other key gene products involved in intracellular signaling pathways. Changes in gene expression were examined using RT-PCR. The effect of astaxanthin-nanocarbons combinations on cancer cells was also evaluated. Results: Astaxanthin induced cell death in all three breast cancer cell lines was examined so that its IC50 in two HER2-amplifying lines SKBR3 and BT-474 stood, respectively, at 36 and 37 ?M; however, this figure for MCF-7 was significantly lowered to 23 ?M (P<0.05). Astaxanthin-treated SKBR3 cells showed apoptotic death upon co-staining. Our in silico examinations showed that some growth-promoting molecules are strongly bound by astaxanthin via their specific amino acid residues with their binding energy standing below -6 KCa/Mol. Next, astaxanthin was combined with either graphene oxide or carboxylated multi-walled carbon nanotube, with the latter affecting SKBR cell survival more extensively than the former (P<0.05). Finally, astaxanthin coinduced tumor suppressors p53 and PTEN but downregulated the expression of growth-inducing genes in treated cells. Conclusion: These findings indicate astaxanthin carries' multitarget antitumorigenic capacities and introduce the compound as a suitable candidate for combination therapy regimens against cancer growth and drug resistance. Development of animal models to elucidate interactions between the compound and tumor microenvironment could be a major step forward towards the inclusion of astaxanthin in cancer therapy trials.

Download Full-text

Mutation and expression analysis of human BUB1 and BUB1B in aneuploid breast cancer cell lines

Cancer Letters ◽

10.1016/s0304-3835(00)00340-2 ◽

2000 ◽

Vol 152 (2) ◽

pp. 193-199 ◽

Cited By ~ 53

Author(s):

Kenute A Myrie ◽

Melanie J Percy ◽

James N Azim ◽

Christopher K Neeley ◽

Elizabeth M Petty

Keyword(s):

Breast Cancer ◽

Cell Lines ◽

Cancer Cell ◽

Breast Cancer Cell ◽

Expression Analysis ◽

Cancer Cell Lines ◽

Breast Cancer Cell Lines

Download Full-text

Identification of novel microtubule inhibitors effective in fission yeast and human cells and their effects on breast cancer cell lines

Open Biology ◽

10.1098/rsob.210161 ◽

2021 ◽

Vol 11 (9) ◽

pp. 210161

Author(s):

Jun Morishita ◽

Paul Nurse

Keyword(s):

Breast Cancer ◽

Drug Resistance ◽

Fission Yeast ◽

Cell Lines ◽

Cancer Cell ◽

Breast Cancer Cell ◽

Intracellular Transport ◽

Cancer Cell Lines ◽

Human Cells ◽

Breast Cancer Cell Lines

Microtubules are critical for a variety of cellular processes such as chromosome segregation, intracellular transport and cell shape. Drugs against microtubules have been widely used in cancer chemotherapies, though the acquisition of drug resistance has been a significant issue for their use. To identify novel small molecules that inhibit microtubule organization, we conducted sequential phenotypic screening of fission yeast and human cells. From a library of diverse 10 371 chemicals, we identified 11 compounds that inhibit proper mitotic progression both in fission yeast and in HeLa cells. An in vitro assay revealed that five of these compounds are strong inhibitors of tubulin polymerization. These compounds directly bind tubulin and destabilize the structures of tubulin dimers. We showed that one of the compounds, L1, binds to the colchicine-binding site of microtubules and exhibits a preferential potency against a panel of human breast cancer cell lines compared with a control non-cancer cell line. In addition, L1 overcomes cellular drug resistance mediated by βIII tubulin overexpression and has a strong synergistic effect when combined with the Plk1 inhibitor BI2536. Thus, we have established an economically effective drug screening strategy to target mitosis and microtubules, and have identified a candidate compound for cancer chemotherapy.

Download Full-text

Expression analysis of maspin in invasive ductal carcinoma of breast and modulation of its expression by curcumin in breast cancer cell lines

Chemico-Biological Interactions ◽

10.1016/j.cbi.2009.11.019 ◽

2010 ◽

Vol 183 (3) ◽

pp. 455-461 ◽

Cited By ~ 14

Author(s):

Chandra P. Prasad ◽

Gayatri Rath ◽

Sandeep Mathur ◽

Dinesh Bhatnagar ◽

Ranju Ralhan

Keyword(s):

Breast Cancer ◽

Cell Lines ◽

Cancer Cell ◽

Breast Cancer Cell ◽

Invasive Ductal Carcinoma ◽

Expression Analysis ◽

Ductal Carcinoma ◽

Cancer Cell Lines ◽

Breast Cancer Cell Lines

Download Full-text

39 EXPRESSION ANALYSIS OF AURKA UNDER HYPOXIA IN BREAST CANCER CELL LINES

Cancer Treatment Reviews ◽

10.1016/s0305-7372(10)70065-7 ◽

2010 ◽

Vol 36 ◽

pp. S106

Author(s):

D. Fanale ◽

L.R. Corsini ◽

M. Terrasi ◽

V. Amodeo ◽

L. La Paglia ◽

...

Keyword(s):

Breast Cancer ◽

Cell Lines ◽

Cancer Cell ◽

Breast Cancer Cell ◽

Expression Analysis ◽

Cancer Cell Lines ◽

Breast Cancer Cell Lines

Download Full-text

Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression

Biochemical Pharmacology ◽

10.1016/j.bcp.2018.11.005 ◽

2019 ◽

Vol 159 ◽

pp. 52-63 ◽

Cited By ~ 13

Author(s):

Ulises Daniel Orlando ◽

Ana Fernanda Castillo ◽

Mayra Agustina Ríos Medrano ◽

Angela Rosaria Solano ◽

Paula Mariana Maloberti ◽

...

Keyword(s):

Breast Cancer ◽

Drug Resistance ◽

Cell Lines ◽

Cancer Cell ◽

Breast Cancer Cell ◽

Cancer Cell Lines ◽

Breast Cancer Cell Lines ◽

Energy Dependent ◽

Transporter Expression

Download Full-text

Investigation of the Effect of IRAK1/4 Inhibitor on the Expression of P53, Bcl-2, Bax and GALNT14 Genes in Combination with Methotrexate and Topotecan in Breast Cancer Cell Lines

Biointerface Research in Applied Chemistry ◽

10.33263/briac112.91579169 ◽

2020 ◽

Vol 11 (2) ◽

pp. 9157-9169

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

Drug Resistance ◽

Cell Lines ◽

Cancer Cell ◽

Breast Cancer Cell ◽

Interleukin 1 ◽

P53 Gene ◽

Cancer Cell Lines ◽

Breast Cancer Cell Lines

Breast cancer is the most common cancer among women. Chemotherapy is one of the main methods of breast cancer treatment, but its efficacy is affected by drug resistance. Interleukin-1 receptor-dependent kinases (IRAKs) are associated with drug resistance in cancer cells. The aim of this study was to investigate the relationship between the expression of p53, Bax, Bcl-2, and GALANT14 in treatment with Methotrexate and Topotecan alone and in combination with IRAK1/4 inhibitor. BT20, BT549, and MB468 breast cancer cell lines were cultured in a specific culture medium, and the effects of Methotrexate and Topotecan with or without IRAK1/4 inhibition on the expression of P53, Bcl-2, Bax, and GALNT14 genes was evaluated by Real-Time PCR. RT-qPCR results showed that the administration of IRAK1/4 inhibitor increased the expression of p53 in all three cell lines treated with Methotrexate and Topotecan. IRAK1/4 inhibitor increased the efficacy of Methotrexate and Topotecan on p53 gene expression. The expression level of the Bcl2 gene was significantly increased in the MB468 cell line treated with Topotecan and IRAK inhibitor + Methotrexate. In the present study, it was found that the IRAK1/4 inhibitor increased the efficacy of Methotrexate and Topotecan on p53 gene expression, thereby inducing apoptosis.

Download Full-text